Atransen Pharma
- Biotech or pharma, therapeutic R&D
Atransen Pharma has been founded in 2022, and is developing a novel LAT1 inhibitor APL1101 for solid tumor chemotherapy, and APL1202 for BNCT therapy.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}